Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
Molnupiravir is an antiviral that forces lethal error catastrophe in SARS-CoV-2 RNAs. Here, the authors confirm the mechanism of action of molnupiravir in humans using samples obtained from the UK’s AGILE phase IIa clinical trial investigating the antiviral efficacy of the drug against SARS-CoV-2. N...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-11-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-022-34839-9 |
| _version_ | 1811187032503877632 |
|---|---|
| author | I’ah Donovan-Banfield Rebekah Penrice-Randal Hannah Goldswain Aleksandra M. Rzeszutek Jack Pilgrim Katie Bullock Geoffrey Saunders Josh Northey Xiaofeng Dong Yan Ryan Helen Reynolds Michelle Tetlow Lauren E. Walker Richard FitzGerald Colin Hale Rebecca Lyon Christie Woods Shazaad Ahmad Dennis Hadjiyiannakis Jimstan Periselneris Emma Knox Calley Middleton Lara Lavelle-Langham Victoria Shaw William Greenhalf Thomas Edwards David G. Lalloo Christopher J. Edwards Alistair C. Darby Miles W. Carroll Gareth Griffiths Saye H. Khoo Julian A. Hiscox Thomas Fletcher |
| author_facet | I’ah Donovan-Banfield Rebekah Penrice-Randal Hannah Goldswain Aleksandra M. Rzeszutek Jack Pilgrim Katie Bullock Geoffrey Saunders Josh Northey Xiaofeng Dong Yan Ryan Helen Reynolds Michelle Tetlow Lauren E. Walker Richard FitzGerald Colin Hale Rebecca Lyon Christie Woods Shazaad Ahmad Dennis Hadjiyiannakis Jimstan Periselneris Emma Knox Calley Middleton Lara Lavelle-Langham Victoria Shaw William Greenhalf Thomas Edwards David G. Lalloo Christopher J. Edwards Alistair C. Darby Miles W. Carroll Gareth Griffiths Saye H. Khoo Julian A. Hiscox Thomas Fletcher |
| author_sort | I’ah Donovan-Banfield |
| collection | DOAJ |
| description | Molnupiravir is an antiviral that forces lethal error catastrophe in SARS-CoV-2 RNAs. Here, the authors confirm the mechanism of action of molnupiravir in humans using samples obtained from the UK’s AGILE phase IIa clinical trial investigating the antiviral efficacy of the drug against SARS-CoV-2. No treatment-associated SARS-CoV-2 mutations were identified. |
| first_indexed | 2024-04-11T13:55:21Z |
| format | Article |
| id | doaj.art-ce55d33708154cc1b4167b313d922661 |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-04-11T13:55:21Z |
| publishDate | 2022-11-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-ce55d33708154cc1b4167b313d9226612022-12-22T04:20:22ZengNature PortfolioNature Communications2041-17232022-11-011311910.1038/s41467-022-34839-9Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trialI’ah Donovan-Banfield0Rebekah Penrice-Randal1Hannah Goldswain2Aleksandra M. Rzeszutek3Jack Pilgrim4Katie Bullock5Geoffrey Saunders6Josh Northey7Xiaofeng Dong8Yan Ryan9Helen Reynolds10Michelle Tetlow11Lauren E. Walker12Richard FitzGerald13Colin Hale14Rebecca Lyon15Christie Woods16Shazaad Ahmad17Dennis Hadjiyiannakis18Jimstan Periselneris19Emma Knox20Calley Middleton21Lara Lavelle-Langham22Victoria Shaw23William Greenhalf24Thomas Edwards25David G. Lalloo26Christopher J. Edwards27Alistair C. Darby28Miles W. Carroll29Gareth Griffiths30Saye H. Khoo31Julian A. Hiscox32Thomas Fletcher33Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of LiverpoolDepartment of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of LiverpoolDepartment of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of LiverpoolDepartment of Evolution, Ecology and Behaviour, Institute of Infection, Veterinary and Ecological Sciences, University of LiverpoolDepartment of Evolution, Ecology and Behaviour, Institute of Infection, Veterinary and Ecological Sciences, University of LiverpoolGCPLab Facility, Institute of Systems, Molecular and Integrative Biology, University of LiverpoolSouthampton Clinical Trials Unit, University of SouthamptonSouthampton Clinical Trials Unit, University of SouthamptonDepartment of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of LiverpoolDepartment of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of LiverpoolDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of LiverpoolDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of LiverpoolDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of LiverpoolDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of LiverpoolNIHR Royal Liverpool and Broadgreen Clinical Research Facility, Liverpool University Hospitals NHS Foundation TrustNIHR Royal Liverpool and Broadgreen Clinical Research Facility, Liverpool University Hospitals NHS Foundation TrustNIHR Royal Liverpool and Broadgreen Clinical Research Facility, Liverpool University Hospitals NHS Foundation TrustNIHR Manchester Clinical Research Facility, Manchester University NHS Foundation TrustNIHR Lancashire Clinical Research Facility, Lancashire Teaching Hospitals NHS Foundation TrustNIHR Kings Clinical Research Facility, King’s College Hospital NHS Foundation TrustSouthampton Clinical Trials Unit, University of SouthamptonSouthampton Clinical Trials Unit, University of SouthamptonGCPLab Facility, Institute of Systems, Molecular and Integrative Biology, University of LiverpoolGCPLab Facility, Institute of Systems, Molecular and Integrative Biology, University of LiverpoolGCPLab Facility, Institute of Systems, Molecular and Integrative Biology, University of LiverpoolCentre for Drugs and Diagnostics, Liverpool School of Tropical MedicineLiverpool School of Tropical MedicineHuman Development and Health School, University of SouthamptonDepartment of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of LiverpoolNIHR Health Protection Research Unit in Emerging and Zoonotic InfectionsSouthampton Clinical Trials Unit, University of SouthamptonDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of LiverpoolDepartment of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of LiverpoolNIHR Health Protection Research Unit in Emerging and Zoonotic InfectionsMolnupiravir is an antiviral that forces lethal error catastrophe in SARS-CoV-2 RNAs. Here, the authors confirm the mechanism of action of molnupiravir in humans using samples obtained from the UK’s AGILE phase IIa clinical trial investigating the antiviral efficacy of the drug against SARS-CoV-2. No treatment-associated SARS-CoV-2 mutations were identified.https://doi.org/10.1038/s41467-022-34839-9 |
| spellingShingle | I’ah Donovan-Banfield Rebekah Penrice-Randal Hannah Goldswain Aleksandra M. Rzeszutek Jack Pilgrim Katie Bullock Geoffrey Saunders Josh Northey Xiaofeng Dong Yan Ryan Helen Reynolds Michelle Tetlow Lauren E. Walker Richard FitzGerald Colin Hale Rebecca Lyon Christie Woods Shazaad Ahmad Dennis Hadjiyiannakis Jimstan Periselneris Emma Knox Calley Middleton Lara Lavelle-Langham Victoria Shaw William Greenhalf Thomas Edwards David G. Lalloo Christopher J. Edwards Alistair C. Darby Miles W. Carroll Gareth Griffiths Saye H. Khoo Julian A. Hiscox Thomas Fletcher Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial Nature Communications |
| title | Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial |
| title_full | Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial |
| title_fullStr | Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial |
| title_full_unstemmed | Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial |
| title_short | Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial |
| title_sort | characterisation of sars cov 2 genomic variation in response to molnupiravir treatment in the agile phase iia clinical trial |
| url | https://doi.org/10.1038/s41467-022-34839-9 |
| work_keys_str_mv | AT iahdonovanbanfield characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT rebekahpenricerandal characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT hannahgoldswain characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT aleksandramrzeszutek characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT jackpilgrim characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT katiebullock characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT geoffreysaunders characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT joshnorthey characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT xiaofengdong characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT yanryan characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT helenreynolds characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT michelletetlow characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT laurenewalker characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT richardfitzgerald characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT colinhale characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT rebeccalyon characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT christiewoods characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT shazaadahmad characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT dennishadjiyiannakis characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT jimstanperiselneris characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT emmaknox characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT calleymiddleton characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT laralavellelangham characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT victoriashaw characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT williamgreenhalf characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT thomasedwards characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT davidglalloo characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT christopherjedwards characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT alistaircdarby characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT mileswcarroll characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT garethgriffiths characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT sayehkhoo characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT julianahiscox characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial AT thomasfletcher characterisationofsarscov2genomicvariationinresponsetomolnupiravirtreatmentintheagilephaseiiaclinicaltrial |